Global Thrombosis Drug Market to Register a CAGR of 9.51% by 2028

The global thrombosis drug market is likely to grow from $25,892 million in 2021 to $47,789 million by the end of 2028. The global market is anticipated to show exceptional growth with an impressive CAGR of 9.51% during the forecast period. The report presents comprehensive projections on the growth factors, opportunities, and restraining factors.

Thrombosis is the medical condition of the emergence of clots in the blood vessels of a human body. Thrombosis drugs are used to treat previous clots or prevent the occurrence of new blood clots. Drugs used to treat thrombosis are most commonly known as anticoagulants. Thrombosis treating drugs are of two main types. One comes in a solution form and can be injected with the help of a syringe and another comes as a pill to be taken orally. The global thrombosis drug market has a prevalence in the treatment of diseases like atrial fibrillation, deep-vein thrombosis (DVT), and pulmonary embolism.

Covid-19 negatively impacted the global market owing to the diversion of all medical assistance for the treatment of Covid-19 patients.

However, now that Covid-19 is under control, the global market is anticipated to register a high revenue share during the forecast period.

The rising number of senior population suffering from morbid diseases is expected to propel the global thrombosis drug market growth during the projection period. The increasing number of trauma cases is anticipated to push the global market forward. The increasing prevalence of a sedentary lifestyle amongst most of the world population is anticipated to become a leading global market growth driver during the forecast period. Extensive research on advanced thrombosis drugs along with increasing investment in medical infrastructure across the globe is anticipated to assist in global market growth.

Lack of awareness amongst the population about thrombosis drugs along with critical side effects due to prolonged use of anticoagulants is likely to restrain the global market growth during the forecast period. The growing disposable income of people is further encouraging them to adopt complete and successful treatment, which is likely to expand the scope of the global market.

The global thrombosis drug market can be segmented into disease type, distribution channel, drug class, and region. By disease type, the market can be segmented into atrial fibrillation, pulmonary embolism, and deep vein thrombosis. By distribution channel, the market can be segmented into retail pharmacies, hospital pharmacies, and online pharmacies. By drug class, the market can be segmented into heparin, Xa inhibitor, and P2Y12 platelet inhibitor.

The global thrombosis drug market is expected to be led by North America which is anticipated to contribute the highest revenue in the global market share. This is owed to the rising geriatric population along with patients suffering from cardiovascular diseases. Unhealthy food eating habits and a rising obesity index in the region are expected to contribute to the global market growth.

Asia-Pacific and Europe are expected to contribute significantly to the global market because of rising R&D in the regions for better thrombosis drugs. Increasing awareness amongst the population about the benefits of thrombosis drugs is anticipated to assist in the upward global market trend in these regions.

Latin America & Africa are expected to register slow CAGR during the forecast period because of the absence of proper healthcare facilities and less investment in medical up-gradation in these regions. Ignorance amongst the population regarding thrombosis drugs is anticipated to restrict the global market share of these regions.

Recent Developments:

• Mylan N.V. revealed that it had signed an agreement to take over Aspen Pharmacare Holdings Ltd. in Europe in September 2020.
• Some of the significant players in the global thrombosis drug market include Pfizer, Aspen Pharmacare Holdings Limited, Bayer AG, AstraZeneca plc, Sanofi, Johnson & Johnson, Bristol-Myers Squibb Company, Baxter International Inc., Boehringer Ingelheim GmbH, and GlaxoSmithKline plc.

Browse the full “Global Thrombosis Drug Market By Disease Type (Deep Vein Thrombosis, Pulmonary Embolism, And Atrial Fibrillation), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, And Retail Pharmacies), By Drug Class (P2Y12 Platelet Inhibitor, Xa Inhibitor, And Heparin), And By Region - Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2022 – 2028.” Report at https://www.zionmarketresearch.com/report/thrombosis-drug-market

Global thrombosis drug market is segmented as follows:

By Disease type

• Deep vein thrombosis
• Pulmonary embolism
• Atrial fibrillation

By Distribution channel

• Online pharmacies
• Hospital pharmacies
• Retail pharmacies

By Drug class

• P2Y12 platelet inhibitor
• Xa inhibitor
• Heparin

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com